Finance

Lists
Why is BBOT up 3,54%?
Dive Deeper
BBOT:NASDAQ
BridgeBio Oncology Therapeutics Inc
US$3,94
+3,54%
(+0,13) 1D
29 ກ.ຍ., 12 ໂມງ 43 ນາທີ 21 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBOT...
Open
US$3,83
High
US$4,02
Low
US$3,80
Mkt. cap
316,29 ລ້ານ
Avg. vol.
576,87 ພັນ
Volume
257,50 ພັນ
52-wk high
US$14,87
52-wk low
US$3,79
EPS
US$-3,04
Shares outstanding
80,17 ລ້ານ
No. of employees
88
Open
US$3,83
High
US$4,02
Low
US$3,80
Mkt. cap
316,29 ລ້ານ
Avg. vol.
576,87 ພັນ
Volume
257,50 ພັນ
52-wk high
US$14,87
52-wk low
US$3,79
EPS
US$-3,04
Shares outstanding
80,17 ລ້ານ
No. of employees
88
About BridgeBio Oncology Therapeutics Inc
CEO-
Employees88
Founded2016
HeadquartersSouth San Francisco, ແຄລິຟໍເນຍ, ສະຫະລັດ
SectorBiotechnology
Websitebbotx.com
Analyst ratings
Based on 9 analysts giving stock ratings to BBOT in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for BBOT in the last 3 months.
Highest
Current US$3,94
US$25,00 (+533,71%)
Average
US$21,00 (+432,32%)
Lowest
US$15,00 (+280,23%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andrew Berens
Leerink Partners
Buy
Reiterated
US$25,00
+533,7%
09/18/2026
Priyanka Grover
J.P. Morgan
Buy
Reiterated
-
-
09/15/2026
Unknown Analyst
Wedbush
Buy
Maintained
US$25,00
+533,7%
09/09/2026
Biren Amin
Piper Sandler
Buy
Maintained
US$21,00
+432,3%
09/09/2026
Sean McCutcheon
Raymond James
Buy
Maintained
US$22,00
+457,7%
09/09/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
US$15,00
+280,2%
09/09/2026
John Newman
Canaccord Genuity
Buy
Maintained
US$20,00
+407%
09/09/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
US$18,00
+356,3%
08/17/2026
Unknown Analyst
J.P. Morgan
Buy
Reiterated
US$25,00
+533,7%
08/14/2026
Mazahir Alimohamed
Oppenheimer
Buy
Reiterated
US$22,00
+457,7%
08/12/2026
David Nierengarten
Wedbush
Buy
Maintained
US$25,00
+533,7%
05/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
US$22,00
+457,7%
05/13/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
US$29,00
+635,1%
05/01/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
35,05 ລ້ານ
38,07 ລ້ານ
39,80 ລ້ານ
49,22 ລ້ານ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14,13 ລ້ານ
5,33 ລ້ານ
6,38 ລ້ານ
10,96 ລ້ານ
Operating expense
49,18 ລ້ານ
43,41 ລ້ານ
46,18 ລ້ານ
60,19 ລ້ານ
Total operating expenses
49,18 ລ້ານ
43,41 ລ້ານ
46,18 ລ້ານ
60,19 ລ້ານ
Operating income
-49,18 ລ້ານ
-43,41 ລ້ານ
-46,18 ລ້ານ
-60,19 ລ້ານ
Other non operating income
980,00 ພັນ
187,00 ພັນ
129,00 ພັນ
182,00 ພັນ
EBT including unusual items
-44,76 ລ້ານ
-38,80 ລ້ານ
-42,11 ລ້ານ
-56,45 ລ້ານ
EBT excluding unusual items
-44,76 ລ້ານ
-38,80 ລ້ານ
-42,11 ລ້ານ
-56,45 ລ້ານ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-44,76 ລ້ານ
-38,80 ລ້ານ
-42,11 ລ້ານ
-56,45 ລ້ານ
Net profit margin
-
-
-
-
Earnings per share
-1,03
-0,49
-0,53
-0,71
Interest and investment income
3,44 ລ້ານ
4,42 ລ້ານ
3,94 ລ້ານ
3,55 ລ້ານ
Interest expense
-
-
-
-
Net interest expenses
3,44 ລ້ານ
4,42 ລ້ານ
3,94 ລ້ານ
3,55 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
-49,11 ລ້ານ
-43,32 ລ້ານ
-46,10 ລ້ານ
-60,11 ລ້ານ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
ແອັບຂອງ Google